View Older Stories View More Recent Stories
-
Pfizer raises and narrows full-year earnings guidance
-
Michael Burry buys puts on Nvidia, Palantir
-
Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance
-
Michael Burry's Scion Asset Management Updates 13F
-
Pfizer earnings preview: Leerink trims estimates
-
Metsera responds to Pfizer litigation amid competing acquisition bids
-
Pfizer (PFE) 2.6 calls to 1 put into quarter results
-
Pfizer files second lawsuit against Novo Nordisk over Metsera acquisition
-
Metsera responds to Pfizer litigation, will address claims in court
-
Pfizer sues Metsera directors and Novo Nordisk over merger breach
-
Pfizer gets early FTC clearance for Metsera acquisition
-
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera
-
Pfizer mulls suing Metsera, Novo Nordisk over topping bid - Semafor
-
Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
-
Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
-
Pfizer calls Novo Nordisk's Metsera bid reckless and illegal
-
ViiV Healthcare's Dovato matches Biktarvy efficacy with less weight gain
-
Pfizer's TUKYSA shows positive results in breast cancer trial
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer to present research data at IDWeek 2025 conference
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
Wells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside
-
Popular stocks with increasing volume: PFE MSTR SMCI INTC PLTR MU NKE AMD SOFI ORCL HOOD COIN
-
Pfizer (PFE) call put ratio 5.7 calls to 1 put with a focus on January 30 and June 35 and 37 calls
-
Trump deal a 'meaningful win' for Pfizer (PFE) - BMO
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Popular stocks with increasing volume: PFE MSTR SMCI INTC PLTR MU NKE AMD SOFI ORCL HOOD COIN
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Is the U.S. drug pricing deal good for Pfizer?
-
TD Cowen on Pfizer (PFE): 'MFN Agreement an Important Positive'
-
Pfizer (PFE) call put ratio 7.5 calls to 1 put with a focus on 10K contracts of March 29 calls as share price up 6.3%
-
Popular stocks with increasing volume: PFE CRWV SOFI INTC HOOD PLTR SNAP AMD NIO ORCL SMCI NKE
-
Trump admin official: we hope to have Trump Rx.gov live early in 2026
-
Pfizer reaches agreement with U.S. government to lower drug prices
-
BMO on Pfizer (PFE) and Trump Deal: 'Announcement serves as a positive to the BioPharma sector'
-
Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients
-
Pfizer Gets Three-year Grace Period From Trump Pharma Tariffs
-
Pfizer CEO Bourla comments on drug deal with Trump admin
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
White House to Announce 'TrumpRx' Drug-Buying Website, and Deal With Pfizer -- WSJ
-
Trump to announce drug-pricing deal with Pfizer -Wapo
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
Pfizer presents cancer data at ESMO 2025 with over 45 abstracts
-
BMO Capital on Pfizer (PFE): 'Metsera Acquisition Moves PFE Back in the Obesity Spotlight'
